Omalizumab for the Treatment of Persistent Drug Induced Urticaria Elicited by Thienopyridines: A Case Report

Author(s): Gianfranco Calogiuri*, Eustachio Nettis, Alessandro Mandurino-Mirizzi, Elisabetta Di Leo, Luigi Macchia, Caterina Foti, Angelo Vacca, Nicholas G. Kounis

Journal Name: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents

Volume 19 , Issue 3 , 2020


DOI : 10.2174/1871523018666190522105055

  Journal Home
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The anti-IgE Omalizumab may be helpful to treat clopidogrel hypersensitivity without stopping thienopyridine administration in patients requirining continuous antiplatellet therapy after coronary stent placement.

Keywords: Clopidogrel, omalizumab, prasugrel, thienopyridines, ticagrelor, urticaria.

[1]
ACC/AHA Guidelines for percutaneous coronary intervention. J. Am. Coll. Cardiol., 2001, 37, 239i-2249i.
[2]
Cheema, A.N.; Mohammad, A.; Hong, T.; Jakubovic, H.R.; Parmar, G.S.; Sharieff, W.; Garvey, M.B.; Kutryk, M.J.; Fam, N.P.; Graham, J.J.; Chisholm, R.J. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J. Am. Coll. Cardiol., 2011, 58(14), 1445-1454.
[http://dx.doi.org/10.1016/j.jacc.2011.06.040] [PMID: 21939827]
[3]
Calogiuri, G.; Mandurino-Mirizzi, A.; Parlangeli, C.; Macchia, L.; Foti, C.; Savage, M.P. Comparing allergist and cardiologist considerations for the optimal management of thienopyridines hypersensitivity. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(1), 2-12.
[http://dx.doi.org/10.2174/1871530318666180914121758] [PMID: 30215337]
[4]
Campbell, K.L.; Cohn, J.R.; Fischman, D.L.; Walinsky, P.; Mallya, R.; Jaffrani, W.; Savage, M.P. Management of clopidogrel hypersensitivity without drug interruption. Am. J. Cardiol., 2011, 107(6), 812-816.
[http://dx.doi.org/10.1016/j.amjcard.2010.11.002] [PMID: 21247516]
[5]
Siu, H.; Kaliyadan, A.; Fischman, D.L.; Nardone, E.; Poll, D.; Savage, M.P. Use of prasugrel in the setting of clopidogrel hypersensitivity: case report and systematic review of the literature. Platelets, 2016, 27(8), 824-827.
[http://dx.doi.org/10.1080/09537104.2016.1203402] [PMID: 27494368]
[6]
Nettis, E.; Cegolon, L.; Di Leo, E.; Canonica, W.G.; Detoraki, A. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real-life experience. Ann. Allergy Asthma Immunol., 2018, 120(3), 318-323.
[http://dx.doi.org/10.1016/j.anai.2017.12.007] [PMID: 29508719]
[7]
Mishra, S.; Connors, L.; Tugwell, B. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature. Diabet. Med., 2018, 35(5), 663-666.
[http://dx.doi.org/10.1111/dme.13591] [PMID: 29381818]
[8]
Ali, A.K.; Hartzema, A.G. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J. Asthma Allergy, 2012, 5, 1-9.
[http://dx.doi.org/10.2147/JAA.S29811] [PMID: 22690127]
[9]
Dobesh, P.P.; Oestreich, J.H. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy, 2014, 34(10), 1077-1090.
[http://dx.doi.org/10.1002/phar.1477] [PMID: 25164528]
[10]
Harris, J.R.; Coons, J.C. Tigacrelor use in a patient with documented clopidogrel hypersensitivity. Ann. Pharmacother., 2014, 48(9), 1230-1233.
[http://dx.doi.org/10.1177/1060028014539143] [PMID: 24958490]
[11]
Scala, E.; Giani, M.; Pastore, S.; Pallotta, S.; Guerra, E.C.; Pirrotta, L.; Locanto, M.L.; Frezzolini, A.; De Pità, O.; Puddu, P. Distinct delayed T-cell response to beta-methasone and penicillin-G in the same patient. Allergy, 2003, 58(5), 439-444.
[http://dx.doi.org/10.1034/j.1398-9995.2003.00117.x] [PMID: 12752333]
[12]
Sánchez-Machín, I.; Iglesias-Souto, J.; Franco, A.; Barrios, Y.; Gonzalez, R.; Matheu, V. T cell activity in successful treatment of chronic urticaria with omalizumab. Clin. Mol. Allergy, 2011, 9, 11.
[http://dx.doi.org/10.1186/1476-7961-9-11] [PMID: 21791043]
[13]
Walters, K.M.; White, A.A. Tolerance to nonsteroidal anti-inflammatory drugs and alcohol after omalizumab treatment in a patient with chronic urticaria. Ann. Allergy Asthma Immunol., 2016, 117(5), 559-561.
[http://dx.doi.org/10.1016/j.anai.2016.08.020] [PMID: 27788887]
[14]
Aksu, K.; Kurt, E. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease. Allergol. Immunopathol. (Madr.), 2013, 41(3), 208-210.
[http://dx.doi.org/10.1016/j.aller.2012.02.005] [PMID: 22763305]
[15]
Hayashi, H.; Mitsui, C.; Nakatani, E.; Fukutomi, Y.; Kajiwara, K.; Watai, K.; Sekiya, K.; Tsuburai, T.; Akiyama, K.; Hasegawa, Y.; Taniguchi, M. Omalizumab reduces cysteinyl leukotriene and 9α,11β- prostaglandin F2 overproduction in aspirinexacerbated respiratory disease. J. Allergy Clin. Immunol., 2016, 137(5), 1585-1587.e4.
[http://dx.doi.org/10.1016/j.jaci.2015.09.034] [PMID: 26559322]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2020
Published on: 21 May, 2019
Page: [335 - 339]
Pages: 5
DOI: 10.2174/1871523018666190522105055

Article Metrics

PDF: 51
HTML: 4



Related Article(s)